medigraphic.com
ISSN 1561-302X (Print)

2021, Number 4

<< Back Next >>

Rev cubana med 2021; 60 (4)

Organ damage clinical and immunological characteristics in patients with idiopathic inflammatory myopathies

Arguelles ZAC, Chico CA, Kokuina E, Casas FN

Language: Spanish
References: 35
Page: 1-16
PDF size: 375.28 Kb.


ABSTRACT

Introduction: Idiopathic inflammatory myopathies constitute a group of muscle diseases characterized by chronic muscle weakness and muscle inflammation of unknown etiology.
Objective: To identify the clinical and immunological characteristics and their relationship with organ damage in patients with idiopathic inflammatory myopathies.
Methods: An observational, descriptive, cross-sectional study was carried out in 52 patients with diagnosis of idiopathic inflammatory myopathy, followed in the protocolized consultation of Rheumatology at Hermanos Ameijeiras Clinical and Surgical Hospital from January 2016 to January 2017. For the qualitative variables, the percentages of each group were calculated. Pearson's Chi-square (Fisher's exact statistic) was used. 95% significance level (α = 0.05) was used to relate the presence of antibodies and the type of myopathy as well as the presence of clinical manifestations of MII.
Results: 80.8% were women and 86.5% of urban origin. The mean age at the beginning was 42.8 ± 13.2 years, time delay to diagnosis was 8.8 ± 7.0 months, mean time of evolution of the disease of 7.5 ± 7.1 years. 80.8% were in remission, 50% had specific antibodies. Hypertension was found in 28.8% of the patients and 23.1% had interstitial pneumonia. Arthritis was present in 96.2%. 26.9% had specific Jo1 antibodies and 21.2% had Ro 52.
Conclusions: Urban female patients in the fourth decade of life predominated, the most frequent specific antibodies found was anti-Jo-1, associated with the presence of interstitial lung disease.


REFERENCES

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis. Engl J Med.1975;292:344-77.

  2. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al.European League Against Rheumatism/American College of Rheumatologyclassification criteria for adult and juvenile idiopathic inflammatory myopathiesand their major subgroups. Ann Rheum Dis. 2017[acceso:08/08/2020];76(12):1955-64. Disponible en:https://www.nejm.org/doi/10.1056/NEJM197502132920706?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

  3. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, et al. Longtermoutcomes in juvenile myositis patients. Semin Arthritis Rheum. 2020[acceso:08/08/2020];50(1):149-55. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934928/

  4. Svensson J, Arkema EV, Lundberg IE, Holmqvist M. Incidence and prevalence ofidiopathic inflammatory myopathies in Sweden: a nationwide population-basedstudy. Rheumatology (Oxford). 2017[acceso: 08/08/2020];56(5):802-10. Disponibleen: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934928/

  5. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics ofinflammatory myopathies. Curr Opin Neurol. 2016[acceso: 08/08/2020];29(5):662-73. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27538058/

  6. Lundberg IE, Tjärnlund A, Bottai M. EULAR/ACR classification criteria for adultand juvenile idiopathic inflammatory myopathies and their major subgroups. AnnRheum Dis. 2017[acceso: 27/7/2020];76(12):1955-64. Disponible en:https://pubmed.ncbi.nlm.nih.gov/29079590/

  7. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies-a guide tosubtypes, diagnostic approach and treatment. Clin Med (Lond). 2017[acceso:27/07/2020];17(4):322-8. Disponible en:https://www.rcpjournals.org/content/clinmedicine/17/4/322

  8. Zamarrón de Lucas E, Carrera LG, Bonilla G, Petit D. Síndrome antisintetasa:análisis de11 casos. Med Clínic. 2017[acceso: 27/07/2020];148(4):166-69. Disponible en:https://medes.com/publication/118377

  9. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol.2018[acceso: 27/07/2020];14(5):290-302. Disponible en:https://pubmed.ncbi.nlm.nih.gov/29674612/

  10. Tieu J, Lundberg I, Limaye V. Idiopathic inflammatory myositis. Best Prac ResClin Rheumatol. 2016[acceso: 27/07/2020];30(1):149-68. Disponible en:https://pubmed.ncbi.nlm.nih.gov/27421222

  11. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies -a guideto subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017[acceso:27/07/2020];17(4):322-28. Disponible en:https://scholar.google.com.cu/scholar?q=Oldroyd+A,+Lilleker+J,+Chinoy+H.+Idiopathic+inflammatory+myopathies&hl=es&as_sdt=0&as_vis=1&oi=scholart

  12. Suzuki S. Integrated diagnosis project for inflammatory myopathies: anassociation between autoantibodies and muscle pathology. Autoimmun Rev.2017[acceso: 27/07/2020];16(7):693-700. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S1568997217301234?via%3Dihub

  13. Mira Bleda E, García Pérez B, Azahara A, García Ortega AA. Miositisnecrotizante autoinmune y dermatomiositis por estatinas: un diagnósticodiferencial complejo. Rev Esp Casos Clin Med Intern (RECCMI). 2019[acceso:27/07/2020];4(2):61-3. Disponible en:https://www.researchgate.net/publication/338889211_Miositis_necrotizante_autoinmune_y_dermatomiositis_por_estatinas_un_diagnostico_diferencial_complejo

  14. Bevilacqua JA, Earle N. Miopatías inflamatorias. Rev Med Clin Condes.2018[acceso: 27/07/2020];29(6):611-21. Disponible en: https://www.elsevier.es/es-revista-revista-medica-clinica-las-condes-202-articulo-miopatias-inflamatorias-S0716864018301172

  15. Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-mediatednecrotizing myopathies: a window on autoimmunity and cancer. Front Immunol.2017[acceso: 27/07/2020];8:992. Disponible en:https://pubmed.ncbi.nlm.nih.gov/28871260/

  16. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patientswith anti OJ (anti isoleucyltRNAsynthetase) autoantibodies. Rheumatology(Oxford). 2007[acceso: 27/07/2020];46(5):842-5. Disponible en:https://academic.oup.com/rheumatology/article/46/5/842/2289414

  17. Shamim E, Rider L, Pandey J. Differences in idiopathic inflammatorymyopathy phenotypes and genotypes between meso American mestizos and northAmerican caucasians. Arthritis Rheum. 2002[acceso: 27/07/2020];46(7):1885-93.Disponible en: https://onlinelibrary.wiley.com

  18. Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients withidiopatic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol.2010[acceso: 27/07/2020];29(12):1381-5. Disponible en:https://link.springer.com/article/10.1007%2Fs10067-010-1465-8

  19. O'Hanlon TP, Miller FW. Genetic risk and protective factors for the idiopathicinflammatory myopathies. Current Rheumatol Rep. 2009[acceso:27/07/2020];11(4):287-94. Disponible en:https://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199906)42:6%3C1285::AID-ANR28%3E3.0.CO;2-1

  20. Gómez Graciela N, Gargiulo MA, Pérez N. Autoantibodies in adult patientswith idiopathic inflammatory. Medicina (B Aires). 2016[acceso:27/07/2020];76(3):129-34.. Disponible en:www.medicinabuenosaires.com/PMID/27295700.pdf

  21. Smoyer Tomic KE, Amato AA, Fernández AW. Incidence and prevalence ofidiopathic inflammatory myopathies among commercially insured, medicaresupplemental insured, and Medicaid enrolled populations: an administrativeclaims analysis. BMC Musculoskelet Disord. 2012[acceso: 27/07/2020];13:103-4.Disponible en:https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-13-103

  22. González Bello Y. Frequency of antinuaclear (ANA), myositis specific (MSA)and myositis associated ntiboides (MAA) in patients with idiopathic inflammatorymyopathies (IIM) from Mexico, Central and South America Centers: data from thePanlar Myositis Study Group. 2015 [acceso: 27/07/2020]29(10). Disponible en:https://acrabstracts.org/abstract/frequency-of-antinuclear-ana-myositis-specificmsa-and-myositis-associated-antibodies-maa-in-patients-with-idiopathicinflammatory-myopathies-iim-from-mexico-central-and-south-america-center/

  23. Campo Voegeli A. Dermatomiositis y sistema del complemento: relación entreactividad de la enfermedad y grado de activación del complemento. Comparación con marcadores bioquímicos tradicionales. (Tesis). España: Universidad deBarcelona. 2013[acceso: 15/7/2020]. Disponible en:https://www.tdx.cat/handle/10803/2222;jsessionid=36A90F00B3B49975A9742F4D4528CDF3#page=1

  24. Kalluru R, Hart H, Corkill M, Ng KP. Long-term follow-up of patients withidiopathic inflammatory myopathy at Waitemata District Health Board. N Z Med J.2016[acceso: 27/07/2020];129(1429):50-6. Disponible en:https://pubmed.ncbi.nlm.nih.gov/26914299/

  25. Maraví TZ, Burgos PI, Prieto González S. Manifestaciones clínicas y anticuerposasociados y específicos de miositis en 15 pacientes chilenos con dermatomiositis:serie clínica en un centro universitario. Rev Méd Chile. 2020 [acceso:27/07/2020];148(2). Disponible en:https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000200160

  26. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis.Curr Rheumatol Rep. 2012[acceso: 27/07/2020];14:275-85. Disponible en:https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000200160

  27. Nuño L, Joven B, Carreira P. Registro de pacientes con miopatía inflamatoriade la Sociedad Madrileña de Reumatología: análisis descriptivo. Reumatol Clin.2019[acceso: 27/07/2020];13(6):331-7l. Disponible en:https://www.reumatologiaclinica.org/es-registro-pacientes-con-miopatiainflamatoria-articulo-S1699258X16300912

  28. Hochbert MC, Feldman D, Stevens MB. Adult onsetpolymyositis/dermatomyositis: An analysis of clinical and laboratory features andsurvival in 76 patients with a review of the literature. Semin Arthritis Rheum.1990[acceso: 27/07/2020];20:114-20. Disponible en:https://linkinghub.elsevier.com/retrieve/pii/0049-0172(86)90014-4

  29. Xicará Sarpeque WE. Caracterización clínica de las miopatías inflamatorias.(Tesis). Guatemala: Universidad de San Carlos de Guatemala. 2014 [acceso:10/7/2020]. Disponible en: http://www.repositorio.usac.edu.gt/643

  30. Torres C, Belmonte R, Carmona L. Survival, mortality and causes of death ininflammatory myopathies. Autoimmunity. 2008[acceso: 27/07/2020];39:205-15.Disponible en:https://www.tandfonline.com/doi/abs/10.1080/08916930600622603?journalCode=iaut20

  31. Lega JC, Fabien N, Reynaud Q. The clinical phenotype associated withmyositis-specific and associated autoantibodies: a meta-analysis revisiting the socalledantisynthetase syndrome. Autoimmun Rev. 2014[acceso:27/07/2020];13:883-91. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174798/

  32. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K. Fourdermatomyositis-specific autoantibodies- TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathiesin a Hungarian cohort. Autoimmun Rev. 2014[acceso: 27/07/2020];13:1211-9.Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S1568997214001554?via%3Dihub

  33. O’Callaghan A, Labrador-Horrillo M, Solans-Laque R. Myositis-specific andmyositis-associated antibodies in a series of eighty-eight Mediterranean patientswith idiopathic inflammatory myopathy. Arthritis Rheum. 2006[acceso:27/07/2020];55(5):791-8. Disponible en:https://onlinelibrary.wiley.com/doi/10.1002/art.22237

  34. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends inpathogenesis, clinical features, and up-to-date treatment recommendations. MayoClin Proc. 2013[acceso: 27/07/2020];88:83-105. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S0025619612010440?via%3Dihub

  35. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysisof dermatomyositis-specific autoantibodies and clinical characteristics inJapanese patients. J Dermatol. 2011[acceso: 27/07/2020];38(10):973-9.Disponible en: https://pubmed.ncbi.nlm.nih.gov/21883412/




2020     |     www.medigraphic.com